Turkey’s Competition Authority launched an investigation into Teva Pharmaceutical Industries for alleged antitrust violations.
Investigators suspect Teva restricted generic drug competition through strategic patent procedures. The company allegedly misled health authorities regarding product efficacy and safety to block market rivals.
The probe targets Teva International, its European subsidiary, and its Turkish unit. This action follows a preliminary inquiry by the Turkish authority.
The company previously faced similar European Commission scrutiny regarding its multiple sclerosis drug, Copaxone.